Jon Congleton - Net Worth and Insider Trading

Jon Congleton Net Worth

The estimated net worth of Jon Congleton is at least $16 Million dollars as of 2026-08-04. Jon Congleton is the CEO of Mineralys Therapeutics Inc and owns about 603,621 shares of Mineralys Therapeutics Inc (MLYS) stock worth over $16 Million. Jon Congleton is also the President and CEO of Alpine Immune Sciences Inc and owns about 5,000 shares of Alpine Immune Sciences Inc (ALPN) stock worth over $324,850. Details can be seen in Jon Congleton's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jon Congleton has not made any transactions after 2026-07-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jon Congleton

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

MLYS Mineralys Therapeutics Inc

98% of holdings · $15.6M

ALPN Alpine Immune Sciences Inc

2% of holdings · $325K

Jon Congleton Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jon Congleton owns 4 companies in total, including Alpine Immune Sciences Inc (ALPN) , Mineralys Therapeutics Inc (MLYS) , and Immunic Inc (IMUX) among others .

Click here to see the complete history of Jon Congleton’s form 4 insider trades.

Insider Ownership Summary of Jon Congleton

Ticker	Company	Transaction Date	Type of Owner
ALPN	Alpine Immune Sciences Inc	2016-06-16	director & President & CEO
MLYS	Mineralys Therapeutics Inc	2026-07-13	director & Chief Executive Officer
IMUX	Immunic Inc	2026-03-27	director
		2026-04-29	director

Jon Congleton Latest Holdings Summary

Jon Congleton currently owns a total of 2 stocks. Among these stocks, Jon Congleton owns 603,621 shares of Mineralys Therapeutics Inc (MLYS) as of July 13, 2026, with a value of $16 Million and a weighting of 98.01%. Jon Congleton also owns 5,000 shares of Alpine Immune Sciences Inc (ALPN) as of June 16, 2016, with a value of $324,850 and a weighting of 1.99%.

Latest Holdings of Jon Congleton

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MLYS	Mineralys Therapeutics Inc	2026-07-13	603,621	26.50	15,995,957
ALPN	Alpine Immune Sciences Inc	2016-06-16	5,000	64.97	324,850

Holding Weightings of Jon Congleton

Jon Congleton Form 4 Trading Tracker

According to the SEC Form 4 filings, Jon Congleton has made a total of 18 transactions in Mineralys Therapeutics Inc (MLYS) over the past 5 years, including 4 buys and 14 sells. The most-recent trade in Mineralys Therapeutics Inc is the sale of 10,700 shares on July 13, 2026, which brought Jon Congleton around $291,468.

According to the SEC Form 4 filings, Jon Congleton has made a total of 0 transactions in Alpine Immune Sciences Inc (ALPN) over the past 5 years. The most-recent trade in Alpine Immune Sciences Inc is the acquisition of 1,250 shares on June 16, 2016, which cost Jon Congleton around $19,350.

Insider Trading History of Jon Congleton

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jon Congleton Trading Performance

GuruFocus tracks the stock performance after each of Jon Congleton's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jon Congleton is 9.76%. GuruFocus also compares Jon Congleton's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jon Congleton within 3 months outperforms 3 times out of 8 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jon Congleton's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jon Congleton

Average Return

Average return per transaction

Outperforming Transactions

1 out of 8 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	3.03
Relative Return to S&P 500(%)	2.09

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Jon Congleton owns.

- MLYS - ALPN

View MLYS Analysis

Jon Congleton Ownership Network

Ownership Network List of Jon Congleton

No Data

Ownership Network Relation of Jon Congleton

Jon Congleton Owned Company Details

What does Alpine Immune Sciences Inc do?

Who are the key executives at Alpine Immune Sciences Inc?

Jon Congleton is the director & President & CEO of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .

Alpine Immune Sciences Inc (ALPN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alpine Immune Sciences Inc (ALPN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alpine Immune Sciences Inc Insider Transactions

No Available Data

What does Mineralys Therapeutics Inc do?

Who are the key executives at Mineralys Therapeutics Inc?

Jon Congleton is the director & Chief Executive Officer of Mineralys Therapeutics Inc. Other key executives at Mineralys Therapeutics Inc include Chief Commercial Officer Eric Warren , Chief Medical Officer David Malcom Rodman , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

Mineralys Therapeutics Inc (MLYS) Insider Trades Summary

Over the past 18 months, Jon Congleton made 9 insider transaction in Mineralys Therapeutics Inc (MLYS) with a net sale of 438,969. Other recent insider transactions involving Mineralys Therapeutics Inc (MLYS) include a net sale of 560,884 shares made by David Malcom Rodman , a net sale of 236,233 shares made by Adam Scott Levy , and a net purchase of 2,841,766 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 269,241 shares of Mineralys Therapeutics Inc (MLYS) in total and bought 0 shares, with a net sale of 269,241 shares. During the past 18 months, 2,403,323 shares of Mineralys Therapeutics Inc (MLYS) were sold and 4,889,260 shares were bought by its insiders, resulting in a net purchase of 2,485,937 shares.

Mineralys Therapeutics Inc (MLYS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mineralys Therapeutics Inc Insider Transactions

No Available Data

What does Immunic Inc do?

Who are the key executives at Immunic Inc?

Jon Congleton is the director of Immunic Inc. Other key executives at Immunic Inc include Chief Executive Officer Erik Lundgren , Chief Medical Officer Michael A. Panzara , and director & other: See Explanation of Responses Biotechnology Value Fund L P .

Immunic Inc (IMUX) Insider Trades Summary

Over the past 18 months, Jon Congleton made no insider transaction in Immunic Inc (IMUX). Other recent insider transactions involving Immunic Inc (IMUX) include a net purchase of 30,000 shares made by Daniel Vitt , a net purchase of 25,024 shares made by Jason Tardio , and a net purchase of 143,075 shares made by Richard Alan Rudick .

In summary, during the past 3 months, insiders sold 0 shares of Immunic Inc (IMUX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunic Inc (IMUX) were sold and 36,310 shares were bought by its insiders, resulting in a net purchase of 36,310 shares.

Immunic Inc (IMUX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunic Inc Insider Transactions

No Available Data

What does Avalyn Pharma Inc do?

Who are the key executives at Avalyn Pharma Inc?

Jon Congleton is the director of Avalyn Pharma Inc. Other key executives at Avalyn Pharma Inc include 10 percent owner & other: See Remark 1 Fmr Llc , 10 percent owner Novo Holdings A/s , and See Remarks Douglas R Carlson .

Avalyn Pharma Inc (AVLN) Insider Trades Summary

Over the past 18 months, Jon Congleton made no insider transaction in Avalyn Pharma Inc (AVLN). Other recent insider transactions involving Avalyn Pharma Inc (AVLN) include a net purchase of 555,555 shares made by Novo Holdings A/s , a net purchase of 555,555 shares made by Sr One Capital Management, Llc , and a net purchase of 277,778 shares made by Jill Carroll .

In summary, during the past 3 months, insiders sold 0 shares of Avalyn Pharma Inc (AVLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Avalyn Pharma Inc (AVLN) were sold and 1,388,888 shares were bought by its insiders, resulting in a net purchase of 1,388,888 shares.

Avalyn Pharma Inc (AVLN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalyn Pharma Inc Insider Transactions

No Available Data

Jon Congleton Mailing Address

Above is the net worth, insider trading, and ownership report for Jon Congleton. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jon Congleton's mailing address is: Radnor Pa 19087.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.